Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The vehicle lotion developed by Actavis is an inactive topical formulation used as a placebo control in Phase 3 clinical trials for head lice infestation. It was specifically designed for use in studies evaluating the therapeutic equivalence of a generic ivermectin lotion 0.5% to the reference listed drug, Sklice. The formulation contains all the excipients of the active drug product but lacks the active pharmaceutical ingredient, ivermectin. As a vehicle control, it serves to establish a baseline for efficacy and safety, ensuring that the observed therapeutic effects in the treatment arm are attributable to the active ingredient rather than the lotion base itself. This vehicle was utilized in randomized, double-blind studies to maintain the integrity of the blinding process and to demonstrate the superiority of the active treatment over the carrier formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vehicle lotion (Actavis).